Cardiovascular Risk Similar in IBD Patients on 5-ASA vs. Immunomodulators or Biologics: Study Findings
Recent findings confirm that biologics and immunomodulators for inflammatory bowel disease (IBD) do not elevate major adverse cardiovascular event (MACE) risk in older patients, aligning with established safety profiles. The ... Read More